NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
MoonLake Immunotherapeutics MLTX
5 fiscal years on record · USD · FY2025 reported · SEC filings only
$-227.3M
$-196.0M
Growth
—
Revenue, FY2025 · full 5-year series below
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
ROE
FY2025 · ROE -60.5%
Each USD of equity lost 61 cents this year.
The 5-year record
5 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue $B | · | · | · | · | · |
| Operating income $B | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 |
| EBITDA $B | −0.2 | −0.1 | −0.1 | −0.1 | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Net income $B | −0.2 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.2 | −0.1 | −0.0 | −0.1 | · |
| EPS, diluted $ | −3.53 | −1.89 | −0.73 | −1.70 | −0.31 |
| Dividend / sh $ | · | · | · | · | · |
| Payout % | · | · | · | · | · |
| ROE % | −60.5 | −25.2 | −13.2 | −268.3 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 1 failures in 20 reconciliationsAUDITED
Reconciled in 4 of 19 fiscal years. 56 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsDecember 31
Data on record since2021